| 2.58 -0.58 (-18.35%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.05  |
1-year : | 12.84 |
| Resists | First : | 7.75 |
Second : | 11 |
| Pivot price | 3.91 |
|||
| Supports | First : | 2.5 |
Second : | 2.08 |
| MAs | MA(5) : | 3.07 |
MA(20) : | 4.58 |
| MA(100) : | 6.51 |
MA(250) : | 8.77 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 2.6  |
D(3) : | 2.4 |
| RSI | RSI(14): 23.1 |
|||
| 52-week | High : | 21.25 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TFFP ] has closed above bottom band by 3.7%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.08 - 3.11 | 3.11 - 3.13 |
| Low: | 2.46 - 2.49 | 2.49 - 2.51 |
| Close: | 2.54 - 2.6 | 2.6 - 2.63 |
Mon, 15 Apr 2024
TFF Pharmaceuticals reports promising Phase 2 trial data By Investing.com - Investing.com
Mon, 15 Apr 2024
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 ... - GlobeNewswire
Tue, 02 Apr 2024
Healthcare Stocks Moving Up and Down Tuesday: NXL, CARM, QTTB, ACB, VERV, TFFP, CDIO, PTPI - InvestorsObserver
Mon, 01 Apr 2024
TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations - Simply Wall St
Thu, 28 Mar 2024
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance
Wed, 27 Mar 2024
TFF Pharmaceuticals reports positive phase 2 trial results By Investing.com - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.23e+006 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.139e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 695.8 % |
| Return on Equity (ttm) | -75.8 % |
| Qtrly Rev. Growth | 733870 % |
| Gross Profit (p.s.) | -49.15 |
| Sales Per Share | -101.51 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.82 |
| Dividend | 0 |
| Forward Dividend | 86600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|